Search results
Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?
Investor's Business Daily· 7 months agoRegeneron Pharmaceuticals is the IBD Stock of the Day as the biotech giant trades near an all-time...
Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'
Investor's Business Daily· 9 months agoShares of REGN stock jumped Monday after the Food and Drug Administration approved Regeneron...
Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers
Investor's Business Daily· 7 months agoRegeneron Pharmaceuticals' high-dose Eylea is off to a strong start in the U.S., the company said...
Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
Investor's Business Daily· 1 year agoConfusion over new Medicare negotiating plans sent Regeneron Pharmaceuticals and Halozyme...
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 2 years agoRegeneron (REGN) closed at $735.96 in the latest trading session, marking a -0.01% move from the...
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
Zacks via Yahoo Finance· 6 months agoShares of Regeneron REGN have gained 10.3% year to date against the industry’s decline of 14.8%....
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance Being Led By Its...
Simply Wall St. via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 22% over the past three...
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding...
Simply Wall St. via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 29% over the past three...
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock Has Fared Decently: Is the Market Following...
Simply Wall St. via Yahoo Finance· 7 months agoMost readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by...
The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line
Investor's Business Daily· 10 months agoRegeneron Pharmaceuticals predicted a faster-than-expected approval timeline for a high dose of its...